abstract |
The present invention relates to an antibody against gremlin-1, which has a therapeutic effect on cancer by inhibiting gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR2). Antibodies of the invention can be usefully used to treat cancer or immune diseases by inhibiting cell migration, cell invasion and cell proliferation, which are dependent on gremlin-1. |